Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530471 | 0.90 | CA14 (0.36) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL15503184 | 0.89 | CTSK (0.35) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL1143116 | 0.87 | SSTR4 (0.41) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL1688918 | 0.87 | CA14 (0.35) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL1896934 | 0.87 | CA14 (0.35) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL20029121 | 0.86 | CA14 (0.34) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL13982487 | 0.86 | CA14 (0.40) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL28733852 | 0.86 | CA14 (0.37) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL4872179 | 0.84 | DPP4 (0.39) | CA14HDAC6HDAC1HDAC2KCNQ4 | |
| SCHEMBL6977019 | 0.84 | CA14 (0.33) | CA14HDAC6HDAC1HDAC2KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025108411-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| US-20240190880-A1 | SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-13 | — | — | US | disclosed |
| US-20240150360-A1 | Small Molecule Degraders of CBP/p300 Proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-09 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11912702-B2 | Substituted pyridines as inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912702-B2 | Substituted pyridines as inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024017372-A1 | INDOLONE DERIVATIVE AND USE THEREOF | 成都百裕制药股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044027-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2006123242-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-6200978-B1 | FOR PREVENTING OR TREATING INFLAMMATORY DISEASES SUCH AS ARTHRITIS, PSORIASIS, ASTHMA, OR INFLAMMATORY BOWEL DISEASE, DISORDERS OF RESPIRATORY FUNCTION, GASTROINTESTINAL DISORDERS SUCH AS FUNCTIONAL BOWEL DISEASE, AS ANALGESICS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | CA14 2417/4885HDAC6 576/4885HDAC1 1104/4885 |
| US-20240150360-A1 | Small Molecule Degraders of CBP/p300 Proteins | EP300, CREBBP, NCOR1 | CA14 3863/4885HDAC6 78/4885HDAC1 4/4885 |
| US-11912702-B2 | Substituted pyridines as inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC3 | CA14 4233/4885HDAC6 9/4885HDAC1 2/4885 |
| US-20240190880-A1 | SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS | ESR1, CRBN, ESR2 | CA14 753/4885HDAC6 4145/4885HDAC1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.